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Summary
Killer-cell immunoglobulin-like receptors (KIRs) are components of two
fundamental biological systems essential for human health and survival.
First, they contribute to host immune responses, both innate and adap-
tive, through their expression by natural killer cells and T cells. Second,
KIR play a key role in regulating placentation, and hence reproductive
success. Analogous to the diversity of their human leucocyte antigen class
I ligands, KIR are extremely polymorphic. In this review, we describe
recent developments, fuelled by methodological advances, that are helping
to decipher the KIR system in terms of haplotypes, polymorphisms,
expression patterns and their ligand interactions. These developments are
delivering deeper insight into the relevance of KIR in immune system
function, evolution and disease.
Keywords: expression; haplotypes; killer-cell immunoglobulin-like recep-
tors; ligands; natural killer cell; polymorphism.
Introduction
Killer-cell immunoglobulin-like receptors (KIRs) are type
I transmembrane glycoproteins belonging to the
immunoglobulin superfamily. They are primarily
expressed on natural killer (NK) cells but they are also
expressed on subsets of CD4, CD8 and cd T cells.1–8
Comprising both activating and inhibitory forms they
represent an archetypal paired receptor system.9 The best
characterized ligands for KIR are HLA class I molecules
that express either the Bw4, C1 or C2 motif (Fig. 1).
The functional activity and development of KIR-
expressing lymphocytes are modulated by interactions
between these receptors and their ligands.12–14 A major
function of circulating cytotoxic NK cells is to recog-
nize and eliminate cells that fail to express self HLA
class I molecules in the surveillance for virus-infected
or transformed cells.15,16 By contrast, a major function
of non-cytotoxic NK cells in the uterus is to secrete
cytokines to regulate placentation during pregnancy.
This occurs through a mechanism of maternal allo-
geneic recognition involving interaction between KIR on
maternally derived uterine NK cells with HLA on fetally
derived cells.17 The KIR system acts to diversify NK cell
stimulation potential through specificity of interaction
and strength of signalling. In this regard, weakly inhibi-
tory KIR/HLA combinations permit a lower threshold
for cell activation than do strongly inhibitory KIR/HLA
combinations.
KIR genes are located in the leucocyte receptor com-
plex on human chromosome 19q13.4. The genes are vari-
ably present in the germline between individuals, forming
haplotypes with diverse gene content (Fig. 2), and
numerous alleles exist for many of the genes. Despite the
major implications of KIR variation for human health it
is known that genome-wide studies have poorly captured
the diversity at the KIR locus. Through focused analyses,
constituent polymorphism has been described at the basic
Abbreviations: HCMV, human cytomegalovirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; KIR, killer-
cell immunoglobulin-like receptors; NK cell, natural killer cell
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levels – gene content of haplotypes, copy number, alleles
and their frequencies. Resulting information has sup-
ported genetic, functional and disease investigation. In
this review we discuss the outstanding challenges in KIR
analysis and the recent methodological developments that
are facilitating new discoveries.
KIR genetics
Functional consequences of KIR polymorphism
Four influential discoveries cultivated the fundamental
principle that genetic variation of KIR has a direct impact
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Figure 1. Killer-cell immunoglobulin-like receptors (KIR) proteins and their ligand interactions. (a) KIR have either two or three
immunoglobulin-like extracellular domains, KIR2D or KIR3D, respectively. They are either activating or inhibitory depending on the structure
of their intracellular domain. Inhibitory KIR have long cytoplasmic tails (KIR**L*) that contain immunoreceptor tyrosine-based inhibitory
motifs (ITIM) that transduce inhibitory signals to the natural killer (NK) cell. Activating KIR have short cytoplasmic tails (KIR**S*) with a
positively charged amino acid residue in their transmembrane region. The charged residue allows KIR proteins to associate with the TYROBP
(DAP12) transmembrane signalling polypeptide, which acts as an activating signal transduction element because it contains an immunorecep-
tor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. KIR3DL1 and KIR3DS1, which are encoded by alleles of the same gene,
KIR3DL1/S1, thus have opposing functions. KIR differentially bind HLA-A, -B or -C allotypes and dimorphisms in the HLA class I a domains
are the major determinants for this interaction. The binding motifs are referred to as C1 and C2 in HLA-C and Bw4 in HLA-B and HLA-A.
The precise KIR binding motif of HLA-A*11, which can be recognized by KIR2DS2, KIR2DS4 and KIR3DL2, has not been determined.10,11
Interactions may also be sensitive to polymorphism outside the HLA and KIR binding motifs and to the presented peptide sequence. The
ligands for activating KIR and some inhibitory KIR are presently not well-defined. OC, open conformers (b) Schematic to show how poly-
morphism in different parts of the KIR and HLA class I molecules diversifies their interactions. Key residues are KIR position 44 and HLA
position 80, which control specificity and KIR position 245 that influences inhibitory signal strength, as discussed in the text.
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on NK cell function, and stimulated ongoing research
into the impact of this variation on human health; (i) the
KIR genomic region has variable gene content,23 (ii) KIR
allelic variation affects KIR allotype function,24,25 (iii)
there are multiple alleles for each KIR gene26 and (iv) this
genetic variation correlates with ability to control disease
or reproduce27–30 (Fig. 3). Even a single nucleotide muta-
tion can dramatically change receptor expression,25,31–33
ligand specificity34–36 or signalling strength. KIR gene
copy number variation influences NK cell education,
shaping the NK cell repertoire.37 Lastly, combinatorial
diversity of KIR and HLA class I alleles also impacts NK
cell function, because any given KIR allotype has differen-
tial reactivity to the allotypes of its cognate HLA class I
ligand.38–43 In this scenario one may expect specific alleles
or combinations to be beneficial for resisting specific
infections, or stimulating immune-mediated disease.44
This combinatorial diversity is amplified by hosting the
KIR and HLA genes on separate chromosomes, and the
result is many millions of different cognate KIR/HLA class
I genotypes, tending to individuality.45,46 Hence, through
evolving multiple genetic mutations in the KIR locus, the
human population probably generates and maintains con-
siderable diversity in immunity to evolutionarily nimble
and diverse pathogens.17 That there is little in common
between human, chimpanzee and orang-utan KIR
loci,47,48 and that distributions of KIR genes track with
ethnicity and geography49–51 are testament to this hypoth-
esis of rapid evolution.
KIR diversity and balancing selection
The interest in KIR genetic variation was piqued from
early studies involving relatively small numbers and sim-
ple methods. The reason is that multiple diverse geno-
types were detected in few individuals23,26,52 and the
only plausible explanation was a highly heterogeneous
genetic system with multiple common variants. These
early studies therefore provided the first evidence that
KIR may be subject to natural selection that maintains
high diversity, just like it does for HLA.19,53 The Yucpa
population from Venezuela has low genomic diversity as
a consequence of serial founder effects.54 There are only
two common KIR haplotypes in the Yucpa (one A and
one B; see Fig. 2 for nomenclature), but between them
they carry all of the expressed KIR genes.55 This situa-
tion is extremely unlikely without the impact of a form
of natural selection called balancing selection, which
maintains genetic variation of specific loci in the popu-
lation.55 Indeed, all human populations studied to date
have a representation of KIR A and B haplotypes51,56
and the prevailing hypothesis is that the A haplotypes
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Figure 2. Structural haplotypes of the KIR gene cluster and recombination mechanisms. Numerous killer-cell immunoglobulin-like receptor
(KIR) haplotypes with different gene content have been described. These haplotypes have been generated through serial duplications and dele-
tions of chromosomal segments containing KIR genes. The distinction between alleles and genes is, therefore, sometimes blurred; for example
KIR2DS3 can be located in two different positions within the KIR locus. (a) The arrangements of genes in 12 common European haplotypes18
are shown. Typically, a person inherits between 14 and 24 KIR genes (between 7 and 12 KIR genes per haplotype). KIR2DP1 and KIR3DP1 are
pseudogenes. Two broad haplotypes exist – A (light blue background) and B (pink background), resulting in genotypes that are an ‘AA’, ‘AB’ or
‘BB’. A haplotypes have a single arrangement of seven expressed genes that encode mostly inhibitory KIR, which are diversified by allelic varia-
tion. B haplotypes have varied gene arrangements and tend to comprise more activating genes and less allelic diversity. The A haplotype can be
divided into two types depending on whether the KIR2DS4 gene is full-length (KIR2DS4) or carries a frameshift deletion (KIR2DS4 del). (b)
Diversity has been generated by homologous recombination, particularly at a recombination hotspot (*) centrally sited within the gene cluster,19
which has shuffled the centromeric (cen) and telomeric (tel) parts of the locus encompassing allelic and gene-content motifs. (c) Further diversity
has been generated through continuing cycles of unequal crossing-over (non-allelic homologous recombination), which result in re-assortment
and addition or subtraction of genes in a ‘cut & paste’-like manner.20,21 So called fusion genes composed of parts of different KIR genes have
been generated by unequal crossover events when the recombination has occurred within genes.21,22
ª 2016 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology 3
The KIR system
are good for fighting infection57,58 whereas B haplotypes
are more beneficial for reproduction.17,59
The impact of balancing selection is also seen clearly in
the DNA sequences of KIR genes.19,38 Namely, a greater
number of common sequences, and greater divergence
between them is present in the KIR locus than would be
expected if there were no selection, and when compared with
other parts of the genome. A good example is KIR3DL1/S1,
which has over 100 alleles characterized (Fig. 4)60 and has
three divergent allele lineages that have been maintained by
balancing selection for millions of years.61 A synergy of pop-
ulation genetics, phylogenetic analysis and comparison of
nucleotide substitution rates among codons showed that this
diversity is focused towards the parts of the KIR molecule
that bind the HLA class I and peptide.61 The prediction that
these major lineages of KIR3DL1/S1 have distinct ligand
HLA/peptide-binding properties has been borne out with
crystallographic and functional studies.35,39,41,42,62–65 Expan-
sion of the phylogenetic analyses to include other KIR mole-
cules revealed natural selection has consistently been focused
towards residues that affect interaction with the HLA class I
ligand,66 as well as those that affect the signalling properties
of the receptor.67
KIR and HLA co-evolution
Specific combinations of cognate KIR and HLA class I
ligand correlate in frequency across the world, indicating
that co-evolution between them continues in modern
humans.69 Again, high-resolution analysis of the Yucpa
population yields further insight into this phenomenon.
The population has extremely high frequency of HLA-C7
and corresponding high frequency of a KIR2DL3 allotype,
unique to the Yucpa, having reduced C7 binding.55 By
comparison, the KhoeSan population from Southern
Africa has one of the highest aggregate frequencies of
HLA-C allotypes expressing the C2 motif. Here, a KIR
allotype that switched binding specificity entirely from C2
to C1 has evolved.34 Both of these binding changes are
due to substitutions at residues subject to balancing selec-
tion (Fig. 5).66 Hence, in both populations it appears that
KIR have been able to respond rapidly and specifically to
HLA class I frequency changes (of unknown aetiology).
In contrast, in the Maori of New Zealand, a very low fre-
quency of HLA-B allotypes expressing the Bw4 motif
(again of unknown aetiology) has been countered by an
increase in frequency of HLA-A allotypes that express
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Figure 3. Major factors that influence natural killer (NK) cell function, expression and killer-cell immunoglobulin-like receptors (KIR) ligand
binding.
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Figure 4. KIR allele counts and KIR3DS1 frequency worldwide plots. (a) Number of alleles reported in the December 2015 release of the IPD
KIR database.60 The advent of killer-cell immunoglobulin-like receptor (KIR) analysis by next-generation sequencing is rapidly increasing the
number of recognized KIR alleles.68 Blue are genes encoding inhibitory KIR, orange activating KIR and grey are pseudogenes. There are 753 alle-
les in total. (b) As an example of how KIR gene frequencies can vary significantly across populations, KIR3DS1 gene frequency across the world
and (c) Europe are shown (data from The Allele Frequency Net Database56).
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KIR ligands.46 Such studies of human populations at high
resolution reveal functionally important changes occur-
ring on a fine scale, the sum of which throughout human
evolution has resulted in the strong signature of balancing
selection throughout the KIR locus.
KIR allelic variation
There is little doubt that the most basic level of pres-
ence/absence of KIR impacts NK cell activity, and that
the number of those genes present can influence NK cell
development37 or control of disease.71 However, the pre-
vailing theme of the genetic studies to date is that anal-
ysis of gene content identifies the fundamental tenets,
which are then refined following higher-resolution analy-
ses of the alleles. This stems from the realization that
KIR alleles have different magnitudes of effect, creating
hierarchical series of phenotypes. From this, testable
hypotheses can be formed about the extent to which
each gene or allele, in conjunction with ligand variation,
can predispose to a phenotype. For example, the cell
surface expression of KIR3DL1 and the ability to recog-
nize HLA-Bw4 ligand vary according to allele, and hence
KIR3DL1 alleles should be analysed accordingly in the
disease context.25,38,58,72 Similarly, polymorphism in the
extracellular domain of KIR2DL1 influences the binding
affinity to HLA-C2.34,40 Over 200 associations of KIR
genes with disease resistance or susceptibility are pub-
lished,56,73 and the handful studied at high resolution
are proving informative.58,74–76 The field is therefore
ripe for harvesting new information through in-depth
analyses.68,77
KIR imputation
A statistical model that infers KIR genotypes from whole-
genome single nucleotide polymorphism data has been
developed with about 97% accuracy for the majority of
KIR genes, and can distinguish the broad A/B haplo-
types.77 This method overcomes many of the obstacles
caused by the complexity of gene content diversity to
enable efficient KIR disease association analyses in large
cohorts, and access to the wealth of previously generated
single nucleotide polymorphism array data.78
KIR disease association studies
Combinations of KIR and HLA class I variants influence
resistance to infections, susceptibility to autoimmune dis-
eases and pregnancy syndromes, as well as outcome after
haematopoietic stem cell transplantation (see The KIR
and Diseases Database; Table 1).79 The influence of HLA
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Figure 5. From discovery to function. Amino acid residues that have been subject to balancing selection can have dramatic effects on HLA class
I recognition. Multiple novel KIR alleles may be discovered during population studies, and molecular analysis identifies the most functionally
important. An example is KIR2DL1*022, which was discovered in the southern African KhoeSan population (a) and which differs from its paren-
tal allele KIR2DL1*001 by a single nucleotide substitution in codon 44 (b).34 Phylogenetic analyses that included the most closely related KIR
from other hominoid species identified that residue 44 has been subject to balancing selection (c).66 Residue 44 occurs at the HLA binding site
in the D1 protein domain of the killer-cell immunoglobulin-like receptors (KIR) molecule (d) (PDB: 1IM9).70 Substitution of methionine 44
(KIR2DL1*001) for lysine 44 (KIR2DL1*022) switches the specificity of the receptor from HLA-C2 to HLA-C1 (e). The methodological pipeline
described above links population-based analyses to functional mapping through sequence/phylogeny analysis and structural biology.
Table 1. KIR and HLA databases and resources
Immuno Polymorphism Database www.ebi.ac.uk/ipd/
Allele Frequency Net Database www.allelefrequencies.net/
dbMHC and dbLRC www.ncbi.nlm.nih.gov/gv/mhc/
www.ncbi.nlm.nih.gov/gv/lrc/
LRC Haplotype Project vega.sanger.ac.uk/info/data/
LRC_Homo_sapiens.html
The Immuno Polymorphism Database (IPD) provides a repository
for killer-cell immunoglobulin-like receptors (KIR) sequences and
includes, allele alignments, fully sequenced KIR haplotypes, donor
KIR B-content group calculator, allele ethnicity tool and primer/
probe search tool.83 The Allele Frequency Net Database (AFND)
provides a repository for KIR allele frequencies and listings of KIR
disease associations.56 dbMHC and dbLRC databases provides
sequences and frequency distributions for alleles of the MHC and
leucocyte receptor complex (LRC) as well as an alignment viewer,
primer/probe search tool and typing kit interface.84 LRC Haplotype
Project provides DNA sequence data from several human LRC hap-
lotypes including contig maps, annotation and a catalogue of all sin-
gle nucleotide polymorphisms and insertions/deletions.85
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class I and KIR gene variation on human immunodefi-
ciency virus (HIV) disease outcome has been particularly
well studied (Fig. 6).80 The variation at these genes has
been described as a double-edged sword because a partic-
ular genotype that confers protection from one disease
(e.g. infection) could bestow increased risk to another
disease type (e.g. autoimmunity or cancer).67,69,81
Population stratification is an important consideration in
KIR association studies. It becomes problematic to anal-
yse genes under strong selection and rapid evolution,
such as the KIR, in admixed (mixed ancestry) populations
where gene frequencies can vary significantly between
subpopulations (Fig. 4). Approaches for KIR genetic anal-
ysis are improving in resolution and throughput (Fig. 7).
Statistical developments offer additional strategies, such
as principle component analysis of ancestry-informative
markers in case–control analysis to address admixture
issues.82
KIR ligand binding
KIR and HLA allotype interactions
Three key advancements have progressed understanding
of the recognition of HLA class I by KIR; (i) the crystal
structures of KIR in complex with their HLA class I
ligands,10,35,70,99 (ii) the development of soluble
KIR36,100,101 and (iii) their use in a multiplex immunoas-
say against a broad panel of HLA class I allotypes102,103
(Fig. 3). These tools have enabled fine-scale analyses of
KIR and HLA class I interaction diversity.
Two-immunoglobulin domain inhibitory KIRs
(KIR2DL1-3) bind HLA-C (Fig. 1). Originally considered
separate genes, KIR2DL2 and KIR2DL3 are now known to
segregate as alleles of the same gene, termed KIR2DL2/3.
Initial studies indicated a simple bipartite system in which
KIR2DL2/3 recognizes HLA-C allotypes with asparagine at
residue 80 (the HLA-C1 motif), and KIR2DL1 recognizes
HLA-C allotypes with lysine at residue 80 (the HLA-C2
motif). Dimorphism at residue 44 of the KIR molecule
causes these specificity differences, where KIR2DL2/3 has
lysine and KIR2DL1 has methionine.36,100,104,105 Crystal
structures showed that K44 of KIR2DL2 forms a hydrogen
bond with the N80 of HLA-C1.99 By contrast, M44 of
KIR2DL1 has no direct contact with HLA-C but forms part
of a charge pocket that accommodates the K80 of HLA-
C2.70 Other residues are involved in the interaction how-
ever, and their polymorphism means that there is a range
of binding characteristics determined by KIR allotype. The
interactions of KIR2DL are further diversified by polymor-
phism within the subsets of C1-bearing and C2-bearing
HLA allotypes.34,103 The basis for these hierarchies may
occur due to polymorphism at sites other than position 80,
or the distinct repertoires of peptide presented by the dif-
ferent HLA-C allotypes.106 An additional feature of HLA-C
polymorphism is the differential cell surface expression
exhibited by individual allotypes,91 although how this vari-
ation impacts NK cell reactivity is yet to be fully defined.
KIR2DL2/3 allotypes form a continuum of binding
strength and specificity that includes several inactivated
or weakened variants.34,40,55,107–109 Studies using soluble
KIR showed that allotype KIR2DL3*001 is C1-specific
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Figure 6. Host genetic variation and functions of HLA class I and
killer-cell immunoglobulin-like receptors (KIR) in human immunod-
eficiency virus type 1 (HIV-1) resistance. HIV-1 down-regulates
HLA class I expression on the surface of infected CD4+ T cells so as
to evade CD8+ T-cell lysis.86,87 However, this action exposes the
infected cells to recognition and lysis by natural killer (NK) cells
through KIRs. The effectiveness of an NK cell response, and conse-
quently the outcome of infection, are linked to the host’s KIR genes,
their copy number and the expression levels of their ligands. More
specifically, resistance to HIV-1 correlates with; (i) the compound
genotype, KIR3DS1 - HLA-B Bw4 (with isoleucine at position 80);
KIR3DS1 binds HLA-F open conformers, which can be expressed on
HIV-infected activated CD4+ T cells.88,89 In this case NK cells
expressing KIR3DS1 could also degranulate more potently in
response to HIV-infected Bw4+ CD4+ T cells and suppress viral
replication.90 (ii) HLA-C alleles that confer high cell surface expres-
sion91,92; this may occur because the higher-expressing HLA alleles
result in highly educated NK cells, in addition to more efficient pre-
sentation of HIV epitopes to cytotoxic T cells, (iii) high expression
KIR3DL1 alleles in Bw4+ individuals; again this could be due to
highly educated KIR3DL1+ NK cells with greater activation potential
when the ligand is down-regulated by HIV,58 (iv) Increased copy
number of KIR3DS1 alone or KIR3DL1 in the presence of HLA-B
Bw4; probably related to the clonal distribution of KIR, whereby the
frequency of NK cells expressing a given KIR correlates linearly with
gene copy number, (v) HLA allotypes that form complexes with
HIV peptides that bind weakly to inhibitory KIR or strongly to acti-
vating KIR. Through any of these mechanisms, NK cells can exert
selection pressure on HIV through KIR.63,93 Conversely, HIV pep-
tides that complex with HLA allotypes and bind inhibitory KIR with
high affinity represent NK cell ‘escape’ variants via inhibition of NK
cell function.94,95
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and binds relatively weakly, whereas KIR2DL2*001 binds
more strongly and has cross-reactivity with C2.103 In addi-
tion to those directly at the binding site, the substitutions
that cause these functional differences may affect the angle
or orientation of the binding domain,55,103 or the efficiency
of receptor clustering at the cell surface.99,108 Allelic poly-
morphism also influences the functional properties of
KIR2DL1, which has evolved to be a highly specific recep-
tor for HLA-C2.110 Yawata et al. first reported that NK cells
educated via KIR2DL1*004 had lower interferon-c produc-
tion than those educated via KIR2DL1*003.111 This occurs
because KIR2DL1*004 has weak affinity for HLA-C2 tar-
gets34 as well as reduced capacity for intracellular signal
generation.112 A single dimorphism in the transmembrane
region determines the signalling capacity; allotypes with
R245 transduce a functional inhibitory signal and those
with C245 have reduced inhibitory signalling.112 Super-
resolution microscopy has revealed that the nanoscale
organization of KIR at cell surfaces depends on the trans-
membrane sequence, which in turn affects downstream sig-
nalling.113 Further modifying the functional range of
KIR2DL1 are polymorphisms in the extracellular and cyto-
plasmic domains that regulate avidity and specificity, as
well as the level of cell-surface expression (Fig. 1).34,40
Like the inhibitory KIR2D, the interactions between
inhibitory KIR3D and their cognate ligands are diversified
by their considerable polymorphism. KIR3DL1 recognizes
HLA-A and HLA-B alleles that encode the Bw4 motif, a
region that spans residues 77–83 on the a-1 helix of the
molecule (Fig. 1).35,114,115 Recognition of Bw4 by
KIR3DL1 is sensitive to polymorphism both within and
outside the Bw4 motif, as well as to the sequence of the
bound peptide.42,63,116–118 Early work showed that HLA-
Bw4 allotypes with I80 formed more potent ligands for
KIR3DL1 than those with T80,119 a functional difference
reinforced by associations with disease outcome.27,58,120–122
However, recent high-resolution studies have identified
several I80 Bw4 allotypes that are poorly recognized by
KIR3DL1, providing weaker KIR3DL1 ligands than selected
T80 Bw4 allotypes.39,41,123 Compounding the difficulty of
understanding the interactions between KIRD3DL1 and
Bw4 is the extensive functional polymorphism of KIR3DL1,
which changes its cell-surface expression25,38 and capacity
to recognize the Bw4 epitope.41,65,123
Activating KIR ligand interactions
Although disease associations27,76,124,125 and sequence
homology67 with their inhibitory counterparts suggest
that activating KIR recognize HLA class I, their cognate
ligands have been harder to identify (Fig. 1). As the body
of research dedicated to activating KIR has grown, it has
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become clear that three conserved features of their biol-
ogy are likely to have hampered the process of ligand dis-
covery; (1) their low affinity for HLA class I,11,40,105,126,127
(2) narrow specificity11,126–128 and (3) high peptide selec-
tivity.10,11,64,127 These features are epitomized by
KIR2DS2*001, which binds weakly to C1-bearing HLA-
C*16:01 and HLA-C*03:02126,127 and recognizes HLA-
A*11:01 in a peptide-dependent manner.10 Another possi-
bility is that activating KIR recognize virus-induced
ligands129,130 or altered self-HLA class I molecules caused
by viral infection. Recent work has identified open con-
formers (not bound to b2-microglobulin or peptide) of
non-classical HLA class I molecule, HLA-F, as ligands of
KIR3DS1.88,89 Because HLA-F can be expressed on acti-
vated or HIV-1-infected lymphocytes, KIR3DS1-HLA-F
interaction could be important in the control of the T-
cell response131 and/or HIV-1 infection.
Activating KIR are less polymorphic than inhibitory
KIR (Fig. 4).132 However, the exploration of functional
allotypic variation in activating KIR is in its infancy, and
several studies point to its potential importance. Exam-
ples include the observation that KIR2DS1 allotypes rec-
ognize C2-bearing HLA-C with a range of avidities40 and
that KIR3DS1*014, but not KIR3DS1*013, recognizes the
HLA-Bw4 epitope.65 Further, epidemiological studies sug-
gest that specific variants of KIR2DS5, for which a ligand
remains elusive, protect against the development of repro-
ductive disorders.76,133
Reporter systems could be useful tools to screen for
activating KIR ligands and peptide influences of inhibi-
tory KIR.129 The reporter cells are constructed to express
the extracellular domains of activating KIR fused to the
human CD3f cytoplasmic domain. Signalling through
these hybrid receptors results in the expression of green
fluorescent protein, which can be detected by flow cytom-
etry. This method proved helpful to show that HLA-F
open conformers are ligands for KIR3DS1.88
KIR peptide-dependence
The emerging field of peptidomics has relevance to the
KIR field because binding of KIR to their respective HLA
class I ligand is peptide-dependent.134 There are different
mechanisms by which viral infection can rapidly and rad-
ically affect the HLA class I peptide repertoire. Some
viruses have evolved to evade NK cell immunity through
the selection of mutations in MHC-presented peptides
that enhance binding to inhibitory NK cell receptors
including the C-type lectin-like CD94:NKG2A heterodi-
mer receptor and KIR2DL3.135,136 Conversely, virus-
induced changes in peptide repertoire may promote bene-
ficial action through KIR by disrupting HLA class I
recognition by inhibitory KIR, releasing constraint on NK
cells to mount a positive clearance response to infected
cells.135 Structural analysis of peptide interaction by NK
receptors and better understanding of the mechanisms by
which viruses evade the NK cell response could assist the
development of novel targeted interventions to exploit
the antiviral activities of NK cells.
KIR gene expression
NK and T-cell KIR repertoire
With the exception of KIR2DL4 and KIR3DL3,137,138 KIR
gene expression is clonally distributed and only a fraction
of NK and T cells express a given KIR. KIR repertoire
formation is complex. At least six factors are recognized
to influence KIR repertoire; (i) transcriptional regulation,
(ii) KIR gene content, (iii) allelic variation, (iv) cellular
differentiation, (v) self-HLA class I ligands and (vi) infec-
tion (Fig. 3).
KIR repertoire formation is governed by bi-directional
promoter activity and epigenetic silencing. High CpG
methylation of the KIR proximal promoter was reported
in NK cells and CD8+ T cells lacking expression of the
corresponding KIR molecule, and vice versa.139–141 KIR
expression requires the intermediate promoter Pro1;142
however, the strength of KIR proximal promoter anti-
sense activity is probably responsible for clonal KIR dis-
tribution in NK and T cells.7,142–144 The relative affinity
of binding sites for transcription factors involved in sense
versus antisense promoter activity determines the proba-
bility of generating the sense transcript required for gene
activation.142,143 A recent mouse study suggests that acti-
vating receptor-mediated signalling might regulate this
process during NK cell development.145 Polymorphisms
in the KIR promotors also impact KIR expres-
sion.142,146,147
Beside epigenetic and transcriptional regulation, KIR
repertoire formation is also dependent on KIR gene con-
tent and allelic variations. Each KIR gene is usually pre-
sent in between zero and three copies in a given
individual. As well as when the gene is absent, KIR
expression is also abolished in individuals that are
homozygous for a null allele, or who only carry the null
allele of the gene – e.g. KIR3DL1*004 null allele is pre-
sent at a mean frequency of 242% (SD 103) in world-
wide populations.56 The frequency of cells positive for a
given KIR is tightly linked to KIR gene copy number; a
donor with two copies of KIR3DL1 will have a greater
frequency of KIR3DL1+ NK cells than donors with only
one copy,37,38,142 suggesting that each KIR gene copy is
regulated independently. Additionally, NK cell KIR
expression is related to cellular differentiation. KIR
expression is weak or absent in immature NKG2A+
CD56bright NK cells and increases gradually with matura-
tion, reaching its maximum level in NKG2A CD56dim
NK cells.148–150 Similar observation was made for T cells,
in which KIR expression is virtually absent in CD4 and
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CD8 naive T cells and reaches its maximal level in differ-
entiated effector memory T cells.2,5,151,152 Accordingly,
KIR expression is low in less mature cord blood NK and
T cells compared with healthy adult control cells.153,154
Unlike T- and B-cell repertoire formation, there is no
evidence for negative selection or deletion of NK cells
expressing a combination of receptors that could be
harmful or useless.108,155 Instead, in a process termed
education, only NK cells expressing self-specific HLA class
I inhibitory receptors (NKG2A or KIR) become fully
functionally competent. The degree to which NK cell edu-
cation shapes the KIR repertoire has been a matter of
debate. Using a mathematical and phenotypic approach,
Andersson et al. demonstrated that an adult’s NK cell
KIR repertoire formation was largely stochastic, in line
with probabilistic expression of KIR under bidirectional
proximal promoter activity and no selection.156 However,
other studies showed a slight but significant bias of the
global KIR repertoire in adults toward the expression of
KIRs able to recognize self-HLA class I.111,157 Paradoxi-
cally, the same authors demonstrated that KIR repertoire
in newborns was not biased toward self-HLA class I
recognition.158 This observation suggested that KIR reper-
toire acquisition was indeed stochastic but the slight bias
observed in adults might be driven by infections encoun-
tered later in life.
In 2004, Guma et al. showed that expression of
NKG2C, an activating receptor for HLA-E, was increased
in individuals infected with the human cytomegalovirus
(HCMV) and that NKG2C+ cells expressed high level of
KIRs.159 It was later demonstrated that these HCMV-
associated NKG2C+ NK cells express self-specific KIRs
and account for the vast majority of adult KIR repertoire
deviation toward self HLA class I.160 HCMV-adapted NK
cells lacking NKG2C expression were also reported, most
of them expressing activating KIRs.160,161 Using a large
NKG2C-deficient cohort, it was recently demonstrated
that adaptive NK cell responses could occur in the
absence of both activating KIRs and NKG2C; however,
these adaptive NK cells also largely display repertoire
deviation toward self-specific inhibitory KIR expres-
sion.162,163 Also, self-specific inhibitory KIR expression is
not required for generating adaptive NK cells but is prob-
ably necessary for optimal functions. Indeed, HCMV+
TAP-deficient individuals, with a considerable decrease of
HLA class I expression at the cell surface, can develop
NKG2C+ adaptive NK cells but these cells remain hypo-
functional.164
Studies reporting adaptive NK cell expansion in various
viral infections including HIV, hepatitis B virus, hepatitis
C virus, chikungunya virus and hantavirus show that
adaptive NK cells only occur in HCMV+ individuals,
perhaps as the result of opportunistic viral reactiva-
tion.165–168 To date, apart from HCMV, no other viruses
have been seen to correlate with the appearance of
adaptive NK cells, and associated KIR repertoire devia-
tions, including herpes simplex virus (both HSV-1 and
HSV-2) and varicella-zoster virus.160,169 Instead, it was
shown that acute Epstein–Barr virus infection induces
NKG2A+ CD57+ expansion lacking KIR expression.170
Altogether, these findings suggest that KIR, and adaptive
NK cells, might have mainly evolved to control HCMV.
Supporting this hypothesis, HCMV developed several
strategies to escape NK cell control.171–173 Viral proteins
induce HLA-E expression while decreasing classical HLA
class I (HLA-A, B and C) expression at the cell surface of
infected cells, allowing the virus to selectively escape
NKG2A+ NK cells and interfere with CD8+ T-cell recog-
nition, respectively.174–177 NKG2C and inhibitory KIR
come into play to counteract this escape strategy of
HCMV. NKG2C allows adaptive NK cells to recognize
HLA-E+ HLA class I infected cells while self-specific
KIR prevent them killing HLA-E+ HLA class I+ non-
infected cells (Fig. 8). This model provides an explanation
for the skewed repertoire in adaptive NK cells seen in
HCMV+ individuals towards inhibitory KIR that recog-
nize self HLA class I. Activating KIRs could play a similar
role to NKG2C and recognize unknown HCMV-induced
ligands, similarly to Ly49H/m157 in mouse.129,130
The role of KIR expression in T cells remains unclear
and most of the studies have focused on CD8 T cells,
which contain the largest KIR+ subset within the T-cell
compartment. Although NK cell KIR repertoire is consid-
ered stable in time, the frequency of KIR+ T cells
increases with age, due to accumulation of terminally dif-
ferentiated T cells.141 Interestingly, HCMV-specific CD8 T
cells almost completely lack KIR expression, and the
specificity of KIR-expressing cells remains largely
unknown.2,5,7,151,179 In contrast, it was shown that
KIR+ CD4+ T cells display specificity against HCMV but
not Epstein–Barr virus or HSV-1.4 It is clear that inhibi-
tory and activating KIR can, respectively, dampen and
co-stimulate T-cell receptor-mediated activation in CD4
and CD8 T cells.5,151,179–182 Unlike NK cells, self-specific
inhibitory KIR expression does not educate T cells, as
they do not display enhanced functional responses upon
T-cell receptor triggering.7 Instead, it was shown that
ex vivo KIR+ effector memory CD8+ T cells were hypore-
sponsive to T-cell receptor triggering compared with
KIR effector memory CD8+ T cells.7 It was proposed
that KIR expression protects from activation-induced cell
death in a ligand-independent manner, perhaps explain-
ing their accumulation with aging.2,183
KIR repertoire analysis
KIR repertoire analysis has proved important in the study
of NK cell function. Future studies will need to systemati-
cally analyse in-depth KIR repertoire of organ resident
NK cells, which are known to display unique KIR
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repertoires, at least in the uterus and the liver.184–186
When studying the KIR repertoire all the parameters that
are known to influence KIR expression should be
considered (Fig. 3), most of all KIR genotypes and cellu-
lar differentiation markers. Cytometry panels require
many colours to include as many KIR as possible,
together with differentiation markers including at least
NKG2A, NKG2C and preferably other markers specific to
adaptive NK cells (e.g. FCeR1c, CD57 and NKp30).
Strategies for KIR repertoire analysis using high-dimen-
sional FACS analysis were recently described.187 Several
limitations remain in such analysis, such as mis-binding
of antibodies relating to amino acid substitutions in par-
ticular KIR allotypes. For example, anti-KIR2DL3 ECM41
antibody does not recognize KIR2DL3*015 or
KIR2DL3*005.187 These allotypes are recognized by anti-
bodies with specificity for receptors encoded by other
KIR genes (Table 2). New next-generation sequencing
techniques will allow fast and cost-effective KIR typing at
allelic resolution and will facilitate KIR repertoire inter-
pretation.68 In addition, high-dimensional mass cytometry
(mass cytometry by time-of-flight) is a powerful tool for
investigating NK cell repertoire diversity through the
analysis of many cellular markers simultaneously188
(Fig. 9). The approach is being used to characterize the
phenotypes of lymphocytes and their abundance in biop-
sies of patients, to gain insight into, for example, how
receptor genotypes influence disease susceptibility in a
cell-type-specific manner.188–191 Once identified, discrete
NK cell subpopulations associated with disease could be
harnessed for immunotherapeutic strategies or may pre-
dict response to treatment. Combined with other single-
cell techniques, e.g. RNA-Seq, this could be an important
step forward to personalized and more cost-effective
treatment.
Although the new methods are increasing scale and res-
olution of all aspects of KIR study, one obstacle that
future repertoire studies will need to overcome is the cur-
rent lack of antibodies that specifically recognize
KIR2DS2, KIR3DS1, KIR2DS3 and KIR2DS5 (Table 2).
Although antibody combinations can help to decipher
these activating KIRs,187,192,201 they do not allow analysis
at single KIR level because of antibody cross-reactivity.
Aptamers, short single-stranded nucleic acid oligomers
that bind to a specific target molecule, with their unique
features of high binding affinity and specificity, could
offer a useful alternative to antibodies in discriminating
subtly different forms of KIR.209 Improving KIR reper-
toire analysis will contribute to our understanding of
clinical situations where KIR have a proven or suspected
role such as antiviral immune response, transplantation,
autoimmunity and reproduction.
KIR model systems
Mouse NK cells do not express KIR but instead Ly49
receptors (C-type lectin-like type II transmembrane disul-
phide-bonded homodimers), which perform analogous
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Figure 8. Natural killer (NK) cell strategies in human choriomenin-
gitis virus (HCMV) infection. Viral proteins up-regulate HLA-E
expression to selectively inhibit NK cells through the NKG2A inhibi-
tory receptor. Concomitantly, the virus down-regulates classical HLA
class I expression to evade CD8+ T cells. NKG2C allows NK cells to
detect HLA-E+ HLA class I-infected cells. Hence, ‘missing-self’ (no
HLA class I) triggers activation of NK cells already educated/licenced
by self-HLA class I molecules.165,178 Non-infected cells are protected
from NK cell cytotoxicity by recognition of HLA class I by inhibitory
killer-cell immunoglobulin-like receptors (KIR), which curbs activa-
tion through NKG2C. Activating KIR may directly recognize ‘al-
tered-self’ ligands that are induced by the virus.15
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functions.210 For example, like KIR genes, Ly49 genes
encode both activating and inhibitory NK receptors that
regulate NK cell biology through binding MHC class I
molecules. Despite differences between mice and humans
with regard to the immune and reproductive systems, the
mouse has been used to study how imbalance of NK cell
inhibition or activation potential influences pregnancy.211
Humanized mice of homogeneous genetic background
might in the future enable study of individual KIR and
HLA class I variants in isolation.212 Using a mouse trans-
genic for an HLA-B allele that encodes the Bw4 epitope,
a recent study investigated the roles of cell-intrinsic and
cell-extrinsic HLA class I molecules for educating human
NK cells.213
Because mice and humans are so divergent, primates
are used as in vivo models to study NK cell biology. Some
non-human simian species show a comparable level of
diversity and complexity in KIR haplotypes to humans.214
However, there are extensive differences in size and orga-
nization between the KIR loci of higher primate spe-
cies.215 It is evident in primates that different lineages of
KIR genes have been expanded concomitantly with spe-
cies-specific evolution of MHC class I genes.216 In rhesus
macaque, an important animal model of human diseases
such as AIDS, binding of certain KIR is influenced by the
same MHC epitopes (Bw4 and Bw6) that are important
determinants of human KIR interactions.217 In the last
decade, progress has been made in characterizing KIR
Table 2. Specificities and reported cross-reaction of killer-cell immunoglobulin-like receptors (KIR) antibodies
Clone Specificity Reported cross-reaction and (comments) Reference
143211 KIR2DL1 KIR2DS5 192
HP-3E4 KIR2DL1 KIR2DS1 and KIR2DS4 193
EB6 KIR2DL1, KIR2DS1 KIR2DL3*005 187,194,195
11PB6 KIR2DL1, KIR2DS1 KIR2DL3*005 194
HP-MA4 KIR2DL1, KIR2DS1 KIR2DS3 and KIR2DS5 192,193
GL183 KIR2DL2, KIR2DL3, KIR2DS2 196–198
DX27 KIR2DL2, KIR2DL3, KIR2DS2 52
CH-L KIR2DL2, KIR2DL3, KIR2DS2 199
180701 KIR2DL3 (Does not recognize KIR2DL3*005 and *015) 187
ECM41 KIR2DL3 (Does not recognize KIR2DL3*005 and *015) 194
UP-R1 KIR2DL5 200
1F12 KIR2DS2, KIR2DL3 201
179315 KIR2DS4 140
JJC116 KIR2DS4 KIR2DS3 192
FES172 KIR2DS4 202
DX9 KIR3DL1 203
5133 KIR3DL1, KIR3DL2 All KIRs except KIR2DS1 and KIR2DS3 192
Z27 KIR3DL1, KIR3DS1 204–206
DX30 KIR3DL1/KIR3DL2 207
DX31 KIR3DL2 207
NKVFS1 PanKIR2D 208
Sequence homogeneity between KIR genes at the genomic level translates to high similarity between encoded protein products. As such, analysis
of KIR expression is not trivial in primary cells because of the cross-reaction of available antibodies, in particular between activating and inhibi-
tory isoforms. This can lead to misinterpretation of cell-staining results. These cross-reactions must be taken into account when analysing KIR
expression. Staining experiments can be supported with control stains, references, representative stains on relevant donors and precise descrip-
tions of strategies for differential staining using sets of antibodies.
Patient/tissue sample
NK cell isolation Phenotypic diversity
Identification of 
disease/tissue-
associated subsets
Data visualization
Control/tissue sample
Figure 9. Natural killer (NK) cell analysis by mass cytometry by time-of-flight. By interrogation of multiple markers simultaneously, cell pheno-
types can be compared between, for example, patients versus controls or between different tissue sites. The approach allows alterations in lym-
phocyte composition or abundance to be detected that are linked to killer-cell immunoglobulin-like receptors (KIR) genotypes and disease.
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genes in primates and developing specific genotyping
assays.218,219 Specific interactions between KIRs of pri-
mates and MHC class I ligands are being identified and
monoclonal antibodies against primate KIR proteins are
being generated.220,221 These advances are enabling
phenotypic characterization of KIR expression on NK
cells and T-cell subsets in primates and investigation of
KIR-MHC biology in primate models of infectious
disease.222–224
Therapeutic intervention
As KIRs are expressed on effector cells such as adaptive
NK cells and effector memory T cells, which have under-
gone clonal expansion, it is not surprising that KIRs are
often found expressed on malignant cells. For instance, in
NK and T-cell large granular lymphocytosis lymphocytes
often express activating or inhibitory KIRs in a clonal
manner.225–228 Patients with Sezary syndrome typically
display CD4+ T cells expressing KIR3DL2, which might
contribute to disease onset.228,229 For this reason, KIR are
considered as a potential therapeutic target because they
are only expressed on a small subset of normal lympho-
cytes, the deletion of which is unlikely to be harmful.230
Genetic information on KIR and HLA is already being
used clinically to choose donors for haematopoietic stem
cell transplantation for optimal outcome.231 Indeed, it is
estimated that a significant reduction of relapse after
transplantation for acute myeloid leukaemia can be
achieved by choosing donors based on their KIR and
HLA class I genotype.232,233 This could be extended in the
future to help, for example, sperm donors with the lowest
risk of adverse pregnancy outcomes in assisted reproduc-
tion. In-depth understanding of the molecular pathways
that control NK cells will be critical to the therapeutic
manipulation and in adoptive transfer strategies of these
powerful lymphocytes,234 such as in cancer immunother-
apy.16,29,235,236 Immune-modulation therapies that alter
NK and T-cell function are already in development. For
example Lirilumab, the monoclonal antibody that binds
KIR, is currently in a phase II clinical trial for lym-
phoma.237 By blocking the interaction of inhibitory KIR
with their HLA class I ligands this antibody facilitates
activation of NK cells by impeding inhibitory signalling,
potentially promoting destruction of tumour cells.
Conclusion
Analysis of complex genomics represents a significant
new frontier for immunology. Challenges lie in determin-
ing allelic copies precisely and developing molecular and
computational strategies to analyse them at the scale
required to definitively relate them to phenotypes. For
the KIR gene cluster this process is underway and yielding
valuable insights. KIR, therefore, provide a useful model
for developing analysis methods for other families of pro-
teins shaped by multi-allelic copy number variation,
immune-related or otherwise. An important advance has
been the development of targeted techniques and bioin-
formatics tools to precisely type and analyse HLA and
KIR copy number and alleles with great accuracy and in
high sample numbers. Understanding how KIR variation
influences the initiation and progression of disease will be
achieved through the application of these novel methods
in multidisciplinary projects involving geneticists, statisti-
cians, structural biologists, immunologists and clinicians.
The overarching question is how the signals from lympho-
cyte receptor interactions determined at the genetic level
translate to differing functionality and outcomes in settings
of infections, pregnancy, autoimmunity and cancer. Under-
standing the cellular and molecular mechanisms underlying
the KIR-HLA system will contribute to the development of
interventions and therapies to ameliorate adverse conse-
quences when these mechanisms go awry.
Summary
The advent of next-generation sequencing is set to allow
the determination of KIR and HLA sequences at super-
resolution. Combining such studies with high-resolution
functional mapping of these polymorphic genes will pro-
vide unprecedented insight, not only into the molecular
mechanisms that govern the interactions between receptor
and ligand, but also into the pathophysiology of infec-
tious and non-infectious disorders in which KIR and
HLA play critical roles.
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